| Nemaura Medical (NASDAQ: NMRD) Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm |
| |
|
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) for use by diabetics and pre-diabetics, announced the grant of U.S. Patent 10,092,224, Cumulative Measurement of an Analyte.
SugarBEAT® CGM utilizes a proprietary, daily disposable adhesive skin-patch system connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.
The newly granted patent allows sensing to occur in sub-five-minute intervals by allowing for cumulative measurements to be taken and processed by the algorithm rather than waiting for complete depletion of glucose concentrations.
Globally, there are more than 400M diabetics and 1B pre-diabetics. The annual addressable market for CGM for diabetics (excluding pre-diabetics) is estimated at $82B, with the U.S. market estimated at $13B. CGM adoption among diabetics is growing rapidly; the U.S. market saw 117% growth in 2018.
The Backstory: Nemaura Medical Inc. is a medical technology company developing SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (“CGM”) designed to help people with diabetes and pre-diabetics better manage their glucose levels by spending more time in range. Insulin users can adjunctively use SugarBEAT® when calibrated by a finger stick reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a small form factor rechargeable transmitter, connected via Bluetooth to a specially designed mobile application, which displays glucose readings at five-minute intervals throughout the day.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| GSRX Industries Inc. (OTC: GSRX) Announces Strong 1st Quarter Sales at the Company’s Six Dispensaries in Puerto Rico and California |
| |
|
GSRX Industries Inc. (OTC: GSRX) provided guidance that January sales have been stronger than projected at the Company’s five owned-and-operated Green Spirit RX medicinal cannabis dispensaries in Puerto Rico, and at the Company’s owned-and-operated Green Room dispensary in Point Arena, California.
Average daily sales across GSRX retail dispensaries rose to $26,211. during the current quarter-to-date, an increase of 49% over 4th quarter 2018 ($17,612.), and an increase of 271% over 3rd quarter 2018 ($7,065.). Given the dramatic rise in sales, management is adjusting its performance expectations upward, and anticipates revenues of $2.6 - $2.7 million for 1st quarter 2019.
In addition, the Company’s gross profit margins have steadily increased to 52% during the current period, up from 44% in 3rd quarter 2018 and 47% in 4th quarter 2018.
Key Quote: “Retail sales for January have surpassed our expectations, and our recently launched website GetPureAndNatural.com is posting strong sales.” GSRX CEO Les Ball
The Backstory: GSRX Industries Inc., through its subsidiaries, is in the business of acquiring, developing and operating retail cannabis dispensaries, and is in the process of expanding its business to include the cultivation, extraction, manufacture and delivery of cannabis and cannabinoid products. Currently, GSRX operates five cannabis dispensaries in Puerto Rico under the name Green Spirit RX, one dispensary in California under the name The Green Room, and has five additional pre-qualified locations in Puerto Rico, all of which are in various phases of development and construction. GSRX also owns and operates the e-commerce site GetPureAndNatural.com, which offers a broad range of pharmaceutical grade CBD products.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services and 50,000 shares for investor awareness services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| Spectrum Global Solutions (OTCQB: SGSI) Reduces Debt and Strengthens Balance Sheet |
| |
|
Spectrum Global Solutions, Inc. (OTCQB: SGSI), a multi-national single-source provider of next-generation communications network professional services and software solutions to telecommunications and enterprise markets, announced that it was able to utilize an equity investment received in connection with the previously reported merger with WaveTech Global of approximately $1.1 Million to satisfy the debt owed to Libertas Funding LLC, (“Libertas”) that was incurred in connection with the Company’s acquisition of TNS.
Key Quote: “Our ability to satisfy the Libertas debt within 30 calendar days saved the Company thousands of dollars and freed up additional cash that was being used for amortization payments.” Roger Ponder, CEO of Spectrum
The Backstory: Spectrum Global Solutions operates through its subsidiaries, AW Solutions, ADEX Corp and TNS. The Company is a leading provider of telecommunications engineering and infrastructure services across the United States, Canada, Puerto Rico, Guam and Caribbean. For more information about the Company and its technologies visit the Company’s public filings at www.SEC.gov or the Company’s website at
https://SpectrumGlobalSolutions.com/
Disclosure
Spectrum Global Solutions (OTCQB: SGSI) is a client of RedChip Companies, Inc. SGSI agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
|
Cemtrex (NASDAQ: CETX) Discloses 10 New Leading Enterprises Evaluating SmartDesk for Purchase
|
| |
|
Cemtrex Inc. (NASDAQ: CETX), a leading global technology and manufacturing company, announced that ten new enterprise customers have entered the Cemtrex Enterprise Sales Program, which means they have signed an NDA and are actively performing due diligence of Cemtrex's SmartDesk at their own sites with intent to purchase and integrate into their office and workspace in the coming months.
Key Quote: “We are excited to see such tremendous interest from major corporations in our SmartDesk,” Saagar Govil, Chairman and CEO of Cemtrex
The Backstory: Cemtrex, Inc. (CETX) is a diversified technology company driving innovation in a wide range of sectors, including smart technology, virtual and augmented realities, advanced electronic systems, industrial solutions, and intelligent security systems. Cemtrex is the manufacturer of the SmartDesk, the world’s most advanced workstation. Find us on the web at www.cemtrex.com.
Disclosure
Cemtrex, Inc. (NASDAQ: CETX) agreed to pay RedChip Companies, Inc. a monthly cash fee for three (3) months of investor relation awareness services.
|
|
| |
|
| Atossa Genetics (NASDAQ: ATOS) Reports Results from “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen |
| |
|
Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, updated the status of the pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient who received preoperative oral Endoxifen therapy under an FDA-approved “expanded access” program. The purpose of this therapeutic approach was to reduce activity of the cancer cells prior to surgery.
Key Quote: “We are very encouraged by these results, there is a significant opportunity and need to reduce cancer cell activity prior to surgery. As such, we are currently conducting a Phase 2 study with our proprietary oral Endoxifen in this pre-operative, or ‘window of opportunity,’ setting in Australia.” Dr. Steven C. Quay, President and CEO of Atossa
The Backstory: Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.
|
|
| |
|
|
Zosano (NASDAQ: ZSAN) Announces Publication of Positive Data for Patients with Difficult-to-Treat Migraines
|
| |
|
Zosano Pharma Corporation (NASDAQ: ZSAN), a clinical-stage biopharmaceutical company, announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase 2/3 (ZOTRIP) study in Headache: The Journal of Head and Face Pain, titled “Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult to Treat Migraines.”
Key Quote: “We are pleased with the results of this retrospective analysis, which demonstrate that Qtrypta may be an effective acute treatment for patients exhibiting migraine characteristics that historically have been difficult to treat.” Dr. Stewart Tepper, M.D., Professor of Neurology at the Geisel School of Medicine at Dartmouth
The Backstory: Qtrypta is Zosano’s proprietary formulation of zolmitriptan delivered utilizing its proprietary ADAM technology. Zosano's ADAM technology consists of titanium microneedles coated with drug, and in the case of Qtrypta, its formulation of zolmitriptan. The drug-coated microneedles penetrate through the epidermis, where the investigational drug is dissolved and enters into the bloodstream. In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, in which the 3.8mg dose of Qtrypta met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.
|
|
| |
|
| |
| Quote of the Week |
| |
"If you want to invest in the microcap space, buy companies, not stocks. If you buy stocks, the daily fluctuations and lack of liquidity will drive you crazy."
- Byron Roth, CEO ROTH Capital |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
If you received this email by mistake you can unsubscribe from all emails.
|
|
|
|
|
